Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested β papers, authors, and institutions outside the pilot are not represented. Methodology.
Driven by 1 paper. Top paper: βMUS MGFA Abstractsβ.
phase 3, randomized, double-blind, placebo-controlled CHAMPION MG study (NCT03920293) demonstrated the efficacy and tolerability of the terminal complement C5 inhibitor ravulizumab, administered every 8 weeks +2 more